Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer

医学 胰腺癌 内科学 肿瘤科 癌症 胰腺疾病 放射治疗 疾病 梅德林 癌症研究 胰腺导管腺癌
作者
Brian Matthew Wolpin,Wungki Park,Ignacio Garrido‐Laguna,Alexander I. Spira,Alexander Starodub,David Sommerhalder,Salman Rafi Punekar,Minal A. Barve,Meredith S. Pelster,Benjamin Herzberg,Nilofer Saba Azad,Joel Randolph Hecht,Sai‐Hong Ignatius Ou,Tong Lin,Sumit Kar,Lin Tao,Rashmi Vora,Aparna Hegde,Kyaw Lwin Aung,David S. Hong
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:394 (18): 1790-1802 被引量:130
标识
DOI:10.1056/nejmoa2505783
摘要

BackgroundCurrent therapies for patients with pancreatic ductal adenocarcinoma (PDAC) provide modest benefit. Activating RAS mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate–bound mutant and wild-type RAS. MethodsIn this phase 1–2 study, we evaluated daraxonrasib in patients with advanced solid tumors with activating RAS mutations. Patients received 10 to 400 mg of daraxonrasib orally once daily; 300 mg was selected as the phase 3 dose. The primary end point was safety. Pharmacokinetics and antitumor activity were secondary end points. This report focuses on the 168 study patients with previously treated RAS-mutated PDAC. ResultsAmong the 168 patients with PDAC who received daraxonrasib at a dose of 300 mg or less, treatment-related adverse events of any grade were reported in 96%; such events of grade 3 or higher were reported in 30%. Treatment-related adverse events that occurred in at least 10% of the patients included rash, diarrhea, nausea, stomatitis or mucositis, vomiting, and fatigue. In a subgroup of 26 patients with RAS G12 mutations who were treated with second-line daraxonrasib at a dose of 300 mg, an objective response to therapy was reported in 35% (95% confidence interval [CI], 17 to 56). The median duration of response was 8.2 months (95% CI, 3.8 to not evaluable), with median values of 8.5 months for progression-free survival and 13.1 months for overall survival. Among the 38 patients with RAS G12, G13, or Q61 mutations, 29% (95% CI, 15 to 46) had an objective response. The median duration of response was 8.2 months (95% CI, 3.8 to 8.8), with median values of 8.1 months for progression-free survival and 15.6 months for overall survival. ConclusionsDaraxonrasib was associated with treatment-related adverse events of grade 3 or higher in one third of patients with previously treated RAS-mutated PDAC; antitumor activity was also reported. (Funded by Revolution Medicines; RMC-6236-001 ClinicalTrials.gov number, NCT05379985.)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
欣慰电脑完成签到,获得积分10
刚刚
1秒前
感谢777转发科研通微信,获得积分50
1秒前
山山而川完成签到,获得积分10
1秒前
hh285完成签到,获得积分10
1秒前
达达完成签到,获得积分10
2秒前
litn完成签到 ,获得积分10
2秒前
机智亦云完成签到,获得积分10
3秒前
LYN完成签到,获得积分10
3秒前
今天也不想搬砖完成签到,获得积分10
3秒前
感谢饺子123转发科研通微信,获得积分50
3秒前
zz完成签到 ,获得积分10
3秒前
信仰完成签到,获得积分10
3秒前
奋斗平卉完成签到,获得积分10
4秒前
康敏艳完成签到,获得积分10
4秒前
小梦完成签到,获得积分10
4秒前
爱我不上火完成签到 ,获得积分10
5秒前
科目三的应助被化工兔采纳,获得10
5秒前
怕孤单的新波完成签到,获得积分20
5秒前
感谢醉卧星河转发科研通微信,获得积分50
5秒前
cch完成签到,获得积分10
6秒前
蔡能涛完成签到 ,获得积分10
6秒前
Orange的应助被liqunzhang采纳,获得10
6秒前
cc完成签到 ,获得积分10
6秒前
子非我完成签到,获得积分10
6秒前
衣裳薄完成签到,获得积分10
6秒前
执名之念完成签到,获得积分10
7秒前
臣四水儿完成签到 ,获得积分10
7秒前
英俊的铭的应助被Cx330采纳,获得10
7秒前
感谢sisisi转发科研通微信,获得积分50
8秒前
自由甜瓜完成签到,获得积分10
8秒前
任性的傲柏完成签到,获得积分0
8秒前
Eli发布了新的文献求助10
8秒前
00gi完成签到,获得积分10
8秒前
小冯1完成签到,获得积分10
9秒前
郑瑞完成签到 ,获得积分10
9秒前
清新的石头完成签到,获得积分10
9秒前
好好完成签到,获得积分10
9秒前
yygz0703完成签到 ,获得积分10
9秒前
梨恩完成签到,获得积分20
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808